Shizuko Takahara

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. These oral agents target androgen and androgen receptor signaling and are thought to be less toxic than chemotherapy.(More)
  • 1